In partnership with
Our latest addition to the Biotech Watchlist is exactly the kind of stock that makes biotech investing both fascinating and dangerous.
It is small. It is clinical stage. It does not have earnings. It is not paying a dividend.
Nobody is buying this because the balance sheet screams Ben Graham or because some Wall Street analyst in a vest has decided next quarter’s EBITDA is going to beat by three cents.
This is biotech.
That means the stock is being valued on science, probability, trial design, investor sponsorship, cash runway, market opportunity and the possibility that a small company with a real therapy can become much larger very quickly.
That also means we have to be careful. The Verdad biotech paper makes the point very clearly. Biotech is one of the harshest sectors in public markets.
Since 1996, 67% of U.S. biotechs have had negative cumulative returns, and the median biotech company has produced an annualized return of negative 15%, compared with a positive annualized return for the median U.S. company.
This is not a sector where you throw darts, chant “innovation,” and call that a portfolio. That is not investing. That is cosplay for people who confuse press releases with cash flow.
The right way to approach biotech, according to the Verdad framework, is not to pretend we can personally handicap every clinical trial like a world-class immunologist.
Sponsored Content
The Last Time Stocks Were This Expensive Was December 1999.
"Right now, it's good. But it was in '72, '86, 2000, and 2007." - Jamie Dimon, May 2026.
The Shiller CAPE ratio just hit 42.3. The only time in 140 years it's been higher? December 1999.
Stocks can stay expensive for a long time...
It’s one metric to consider, but when your portfolio is built around the most expensive equities in modern history, what else you diversify with could really matter.
Blue-chip contemporary and post war art has shown near-zero correlation with the S&P since 1995.* Prices are largely driven by private collectors competing for a fixed supply of artwork by artists like Banksy, Basquiat, and Picasso.
Masterworks lets you invest in shares of that market.
$1.3B deployed across 500+ artworks
29 exits to date
Net annualized returns like 16.5%, 17.6%, and 17.8%, not including those unsold
*According to Masterworks data. Investing involves risk. Past performance is not indicative of future returns. See important Reg A disclosures at masterworks.com/cd.
The right approach is to use the data that actually seems to matter in biotech. The paper highlights several important signals: biotech specialist ownership, insider buying, short interest, clinical trial similarity, peer momentum and modified valuation measures that make more sense for companies with no profits. Traditional value metrics often fail in biotech because most of these companies have no earnings.
Verdad argues that investors need biotech-specific definitions of value, quality and momentum.
That is where today’s stock becomes interesting.
This is the part that matters.
No publisher. No overhead. Four strategies built to beat the market.
Get Full AccessPremium members get:
- Small-Cap Momentum Portfolio — beats the market 16 of the last 20 years
- Equity REITs Portfolio — beat the S&P 500 by 10%+ annually since 1972
- Small-Cap Deep Value Portfolio — Walter Schloss used this method to compound at 20% annually for 47 years
- Alternative Fixed Income Portfolio — 10%+ yields, low drama
- Weekly macro video — credit spreads, NFCI, and hard data. No noise, no politics.
- Quarterly biotech watchlist — smart money tracking, insider buying, a decade of backtested data. A hitlist, not a portfolio.